Diosmetin treatment has been reported to inhibit Skp2 expression transcriptionally, and it also downregulates Skp2 expression via inhibition of the SKP2/Bcr-Abl pathway, exhibiting antitumor activity in CML cells and xenograft models (Liu et al., 2020a) (Table 2). Here, SKP2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.